https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-esophageal-cancer-likelihood-of-approval/ 2024-09-09T06:09:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-09-09T06:09:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:09:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-09-09T06:09:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-cervical-cancer-likelihood-of-approval/ 2024-09-09T06:09:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-besylate-rapt-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:09:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tarcocimab-tedromer-kodiak-sciences-non-proliferative-diabetic-retinopathy-npdr-likelihood-of-approval/ 2025-01-21T17:19:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tarcocimab-tedromer-kodiak-sciences-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2025-01-21T17:19:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tarcocimab-tedromer-kodiak-sciences-retinal-vein-occlusion-likelihood-of-approval/ 2025-01-21T17:19:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tarcocimab-tedromer-kodiak-sciences-choroidal-neovascularization-likelihood-of-approval/ 2025-01-21T17:19:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hdp-101-heidelberg-pharma-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-09-09T06:09:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hdp-101-heidelberg-pharma-refractory-multiple-myeloma-likelihood-of-approval/ 2024-09-09T06:09:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/act-001-accendatech-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-09-09T06:09:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/favezelimab-merck-solid-tumor-likelihood-of-approval/ 2024-07-05T18:38:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2025-01-21T17:19:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vla-1601-valneva-zika-virus-infections-likelihood-of-approval/ 2025-01-21T17:19:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/favezelimab-merck-gastric-cancer-likelihood-of-approval/ 2024-07-05T18:38:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitiperstat-astrazeneca-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-21T17:19:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valemetostat-daiichi-sankyo-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T17:19:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/r-327-recce-pharmaceuticals-urinary-tract-infections-likelihood-of-approval/ 2025-01-21T17:19:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rezvilutamide-jiangsu-hengrui-medicine-salivary-gland-cancer-likelihood-of-approval/ 2025-01-21T17:19:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalpiciclib-jiangsu-hengrui-medicine-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T17:19:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avid-200-bristol-myers-squibb-myelofibrosis-likelihood-of-approval/ 2024-09-09T06:08:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T17:18:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsapepimut-io-biotech-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-05-17T03:38:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/soquelitinib-corvus-pharmaceuticals-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-21T17:18:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xt-150-xalud-therapeutics-osteoarthritis-pain-likelihood-of-approval/ 2025-01-21T17:18:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xt-150-xalud-therapeutics-peripheral-neuropathic-pain-likelihood-of-approval/ 2025-01-21T17:18:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ts-23-translational-sciences-acute-ischemic-stroke-likelihood-of-approval/ 2025-01-21T17:18:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1065845-neurocrine-biosciences-treatment-resistant-depression-likelihood-of-approval/ 2024-06-19T16:21:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pentosan-polysulfate-sodium-paradigm-biopharmaceuticals-osteoarthritis-pain-likelihood-of-approval/ 2025-01-21T17:18:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radspherin-oncoinvent-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:18:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camptothecin-podofilox-neovia-oncology-solid-tumor-likelihood-of-approval/ 2024-09-09T06:08:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deucravacitinib-bristol-myers-squibb-ulcerative-colitis-likelihood-of-approval/ 2025-01-21T17:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-urethral-cancer-likelihood-of-approval/ 2025-01-21T17:18:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-ureter-cancer-likelihood-of-approval/ 2025-01-21T17:18:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:18:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-21T17:18:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plamotamab-xencor-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T17:18:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camrelizumab-jiangsu-hengrui-medicine-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T17:18:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zedenoleucel-marker-therapeutics-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T17:18:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zedenoleucel-marker-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T17:18:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tirzepatide-eli-lilly-and-co-obstructive-sleep-apnea-likelihood-of-approval/ 2025-01-21T17:18:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-fulgent-pharma-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-09-09T06:08:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serplulimab-shanghai-henlius-biotech-esophageal-cancer-likelihood-of-approval/ 2025-01-21T17:17:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-fulgent-pharma-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2024-09-09T06:08:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-fulgent-pharma-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-09-09T06:08:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-fulgent-pharma-nasopharyngeal-cancer-likelihood-of-approval/ 2024-09-09T06:08:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-fulgent-pharma-oropharyngeal-cancer-likelihood-of-approval/ 2024-09-09T06:08:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-fulgent-pharma-hypopharyngeal-cancer-likelihood-of-approval/ 2024-09-09T06:08:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-fulgent-pharma-laryngeal-cancer-likelihood-of-approval/ 2024-09-09T06:08:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellular-immunotherapy-to-inhibit-pd-l1-for-oncology-immunitybio-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:17:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sasanlimab-pfizer-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-05T18:37:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellular-immunotherapy-to-inhibit-pd-l1-for-oncology-immunitybio-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2025-01-21T17:17:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellular-immunotherapy-to-inhibit-pd-l1-for-oncology-immunitybio-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T17:17:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellular-immunotherapy-to-inhibit-pd-l1-for-oncology-immunitybio-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T17:17:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellular-immunotherapy-to-inhibit-pd-l1-for-oncology-immunitybio-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:17:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ieramilimab-novartis-metastatic-melanoma-likelihood-of-approval/ 2024-09-09T06:08:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellular-immunotherapy-to-inhibit-pd-l1-for-oncology-immunitybio-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:17:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sucunamostat-scohia-pharma-maple-syrup-urine-disease-likelihood-of-approval/ 2024-05-17T03:26:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sucunamostat-scohia-pharma-nephrotic-syndrome-likelihood-of-approval/ 2024-05-17T03:26:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sucunamostat-scohia-pharma-phenylketonuria-pku-likelihood-of-approval/ 2024-05-17T03:25:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sucunamostat-scohia-pharma-homocystinuria-likelihood-of-approval/ 2024-05-17T03:25:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sintilimab-innovent-biologics-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:17:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/livmoniplimab-abbvie-ovarian-cancer-likelihood-of-approval/ 2025-01-21T17:17:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/livmoniplimab-abbvie-solid-tumor-likelihood-of-approval/ 2025-01-21T17:17:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lmp-744-gibson-oncology-solid-tumor-likelihood-of-approval/ 2025-01-21T17:17:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pdc-lung-pdc-line-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-05-17T03:24:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-endometrial-cancer-likelihood-of-approval/ 2025-01-21T17:17:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:17:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erfonrilimab-alphamab-oncology-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-21T17:17:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anpd-001-aspen-neuroscience-parkinson-s-disease-likelihood-of-approval/ 2024-05-17T03:22:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ritlecitinib-pfizer-keloids-likelihood-of-approval/ 2025-01-21T17:17:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/firicabtagene-autoleucel-cargo-therapeutics-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T17:16:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/firicabtagene-autoleucel-cargo-therapeutics-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-21T17:16:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/firicabtagene-autoleucel-cargo-therapeutics-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T17:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/firicabtagene-autoleucel-cargo-therapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T17:16:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/firicabtagene-autoleucel-cargo-therapeutics-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T17:16:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/firicabtagene-autoleucel-cargo-therapeutics-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T17:16:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/firicabtagene-autoleucel-cargo-therapeutics-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T17:16:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/firicabtagene-autoleucel-cargo-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T17:16:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wt-1312-wintermute-biomedical-herpes-zoster-shingles-likelihood-of-approval/ 2024-05-17T03:19:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/troriluzole-hydrochloride-biohaven-obsessive-compulsive-disorder-likelihood-of-approval/ 2025-01-21T17:16:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T17:15:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ambrisentan-noorik-biopharmaceuticals-hepatorenal-syndrome-likelihood-of-approval/ 2025-01-21T17:15:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cevidoplenib-genosco-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval/ 2024-05-17T03:17:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talabostat-bioxcel-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T17:15:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebs-lassa-emergent-biosolutions-lassa-fever-lassa-hemorrhagic-fever-likelihood-of-approval/ 2024-05-17T03:16:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tregcel-tract-therapeutics-kidney-transplant-rejection-likelihood-of-approval/ 2025-01-21T17:15:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emavusertib-hydrochloride-curis-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2025-01-21T17:15:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anavex-371-anavex-life-sciences-schizophrenia-likelihood-of-approval/ 2025-01-21T17:15:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emavusertib-hydrochloride-curis-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T17:15:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-fibrosarcoma-likelihood-of-approval/ 2025-01-21T17:15:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-synovial-sarcoma-likelihood-of-approval/ 2025-01-21T17:15:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-round-cell-liposarcoma-likelihood-of-approval/ 2025-01-21T17:15:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-pleomorphic-liposarcoma-likelihood-of-approval/ 2025-01-21T17:15:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-dedifferentiated-liposarcoma-likelihood-of-approval/ 2025-01-21T17:15:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-myxoid-liposarcoma-likelihood-of-approval/ 2025-01-21T17:15:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-esophageal-cancer-likelihood-of-approval/ 2025-01-21T17:15:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-peripheral-nerve-sheath-tumor-neurofibrosarcoma-likelihood-of-approval/ 2025-01-21T17:15:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobolimab-gsk-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:14:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:15:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zalifrelimab-agenus-synovial-sarcoma-likelihood-of-approval/ 2024-05-17T03:12:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobolimab-gsk-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T17:14:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zalifrelimab-agenus-pleomorphic-liposarcoma-likelihood-of-approval/ 2024-05-17T03:11:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zalifrelimab-agenus-fibrosarcoma-likelihood-of-approval/ 2024-05-17T03:11:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zalifrelimab-agenus-myxoid-liposarcoma-likelihood-of-approval/ 2024-05-17T03:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zalifrelimab-agenus-round-cell-liposarcoma-likelihood-of-approval/ 2024-05-17T03:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zalifrelimab-agenus-peripheral-nerve-sheath-tumor-neurofibrosarcoma-likelihood-of-approval/ 2024-05-17T03:10:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zalifrelimab-agenus-dedifferentiated-liposarcoma-likelihood-of-approval/ 2024-05-17T03:10:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plx-038-prolynx-solid-tumor-likelihood-of-approval/ 2025-01-21T17:14:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plx-038-prolynx-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T17:14:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lu-satoreotide-ariceum-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:14:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T17:14:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/praliciguat-akebia-therapeutics-focal-segmental-glomerulosclerosis-fsgs-likelihood-of-approval/ 2025-01-21T17:14:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilogrotug-aveo-pharmaceuticals-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:14:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cs-6253-artery-therapeutics-alzheimer-s-disease-likelihood-of-approval/ 2024-05-17T03:07:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilogrotug-aveo-pharmaceuticals-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T17:14:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2059-fusion-pharmaceuticals-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:14:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tavapadon-cerevel-therapeutics-parkinson-s-disease-likelihood-of-approval/ 2024-05-17T03:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2059-fusion-pharmaceuticals-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:14:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2059-fusion-pharmaceuticals-metastatic-prostate-cancer-likelihood-of-approval/ 2025-01-21T17:14:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2059-fusion-pharmaceuticals-ewing-sarcoma-likelihood-of-approval/ 2025-01-21T17:14:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2059-fusion-pharmaceuticals-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T17:14:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selatogrel-idorsia-pharmaceutical-myocardial-infarction-likelihood-of-approval/ 2025-01-21T17:14:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-2059-fusion-pharmaceuticals-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:14:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/triplex-helocyte-biosciences-liver-transplant-rejection-likelihood-of-approval/ 2025-01-21T17:13:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zatolmilast-tetra-therapeutics-fragile-x-syndrome-likelihood-of-approval/ 2024-05-17T03:03:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meningococcal-serotypes-a-b-c-w-135-y-pentavalent-vaccine-gsk-neisseria-meningitidis-infections-likelihood-of-approval/ 2024-05-17T03:02:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cld-101-calidi-biotherapeutics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T17:13:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kus-121-kyoto-drug-discovery-development-retinal-artery-occlusion-likelihood-of-approval/ 2024-05-17T02:59:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eladocagene-exuparvovec-ptc-therapeutics-aromatic-l-amino-acid-decarboxylase-aadc-deficiency-likelihood-of-approval/ 2025-01-21T17:13:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hepatitis-c-vaccine-genecure-biotechnologies-hepatitis-c-likelihood-of-approval/ 2025-01-21T17:13:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abrocitinib-pfizer-dermatological-disorders-likelihood-of-approval/ 2025-01-21T17:13:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amivantamab-johnson-johnson-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:13:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pbf-680-palo-biofarma-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2024-05-17T02:54:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cigb-128-center-for-genetic-engineering-and-biotechnology-brain-tumor-likelihood-of-approval/ 2025-01-21T17:13:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-chronic-idiopathic-myelofibrosis-primary-myelofibrosis-likelihood-of-approval/ 2025-01-21T17:13:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nugel-hudson-therapeutics-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-05-17T02:52:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nerandomilast-boehringer-ingelheim-international-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-21T17:13:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nerandomilast-boehringer-ingelheim-international-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/ 2025-01-21T17:13:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iodine-i-131-apamistamab-actinium-pharmaceuticals-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-21T17:13:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gp-531-vicardia-therapeutics-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2025-01-21T17:13:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iodine-i-131-apamistamab-actinium-pharmaceuticals-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T17:13:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iodine-i-131-apamistamab-actinium-pharmaceuticals-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T17:13:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosmanogepix-basilea-pharmaceutica-candidiasis-likelihood-of-approval/ 2025-01-21T17:13:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iodine-i-131-apamistamab-actinium-pharmaceuticals-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T17:13:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-anaplastic-oligoastrocytoma-likelihood-of-approval/ 2025-01-21T17:12:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-craniopharyngioma-likelihood-of-approval/ 2025-01-21T17:12:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-pituitary-tumor-likelihood-of-approval/ 2025-01-21T17:12:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-leptomeningeal-disease-neoplastic-meningitis-leptomeningeal-carcinomatosis-likelihood-of-approval/ 2025-01-21T17:12:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-meningioma-likelihood-of-approval/ 2025-01-21T17:12:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-oligodendroglioma-likelihood-of-approval/ 2025-01-21T17:12:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-chordoma-likelihood-of-approval/ 2025-01-21T17:12:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-medulloblastoma-likelihood-of-approval/ 2025-01-21T17:12:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-21T17:12:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-anaplastic-astrocytoma-likelihood-of-approval/ 2025-01-21T17:12:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-endometrial-cancer-likelihood-of-approval/ 2025-01-21T17:12:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-thymic-carcinoma-likelihood-of-approval/ 2025-01-21T17:12:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allantoin-paradigm-therapeutics-epidermolysis-bullosa-likelihood-of-approval/ 2025-01-21T17:12:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-bladder-cancer-likelihood-of-approval/ 2025-01-21T17:12:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:12:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aviptadil-relief-therapeutics-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-06-19T16:17:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etripamil-milestone-pharmaceuticals-supraventricular-tachycardia-likelihood-of-approval/ 2024-05-17T02:43:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutikizumab-abbvie-ulcerative-colitis-likelihood-of-approval/ 2025-01-21T17:12:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trevogrumab-regeneron-pharmaceuticals-obesity-likelihood-of-approval/ 2025-01-21T17:11:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enasidenib-mesylate-bristol-myers-squibb-neuroendocrine-carcinoma-likelihood-of-approval/ 2025-01-21T17:11:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enasidenib-mesylate-bristol-myers-squibb-neuroblastoma-likelihood-of-approval/ 2025-01-21T17:11:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-paraganglioma-glomus-jugulare-tumor-likelihood-of-approval/ 2025-01-21T17:11:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enasidenib-mesylate-bristol-myers-squibb-chondrosarcoma-likelihood-of-approval/ 2025-01-21T17:11:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-pheochromocytoma-likelihood-of-approval/ 2025-01-21T17:11:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval/ 2025-01-21T17:11:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:11:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T17:11:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/triheptanoin-ultragenyx-pharmaceutical-neurodegenerative-diseases-likelihood-of-approval/ 2025-01-21T17:11:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qbkpn-qu-biologics-asthma-likelihood-of-approval/ 2024-06-19T16:16:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vididencel-mendus-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T17:11:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nibrozetone-epicentrx-oral-mucositis-likelihood-of-approval/ 2025-01-21T17:11:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/solriamfetol-hydrochloride-axsome-therapeutics-binge-eating-disorder-likelihood-of-approval/ 2025-01-21T17:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naratuximab-emtansine-debiopharm-international-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T06:05:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/st-266-noveome-biotherapeutics-necrotizing-enterocolitis-likelihood-of-approval/ 2025-01-21T17:11:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cenerimod-idorsia-pharmaceutical-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-21T17:11:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naratuximab-emtansine-debiopharm-international-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:05:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabiralizumab-bristol-myers-squibb-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-09-09T06:05:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sevuparin-sodium-modus-therapeutics-endotoxemia-likelihood-of-approval/ 2025-01-21T17:11:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/svt-18651-laboratorios-salvat-dermatitis-eczema-likelihood-of-approval/ 2024-05-17T02:35:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexamethasone-sodium-phosphate-quince-therapeutics-ataxia-telangiectasia-louis-bar-syndrome-likelihood-of-approval/ 2024-09-09T06:05:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stiripentol-biocodex-renal-insufficiency-likelihood-of-approval/ 2024-09-09T06:05:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lmp-400-gibson-oncology-solid-tumor-likelihood-of-approval/ 2024-09-09T06:05:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lmp-776-gibson-oncology-solid-tumor-likelihood-of-approval/ 2024-05-17T02:33:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-3915393-gsk-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-21T17:10:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2025-01-21T17:10:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T17:10:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T17:10:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:10:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2025-01-21T17:10:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T17:10:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/conestat-alfa-pharming-group-acute-ischemic-stroke-likelihood-of-approval/ 2025-01-21T17:07:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T17:10:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-f-hoffmann-la-roche-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:07:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chenodiol-leadiant-biosciences-cerebrotendinous-xanthomatosis-likelihood-of-approval/ 2024-07-05T18:33:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/filgotinib-maleate-alfasigma-giant-lymph-node-hyperplasia-castleman-s-disease-likelihood-of-approval/ 2025-01-21T17:07:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/filgotinib-maleate-alfasigma-polyarticular-juvenile-idiopathic-arthritis-pjia-likelihood-of-approval/ 2025-01-21T17:07:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glasdegib-pfizer-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T17:07:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hu14-18k322a-renaissance-pharma-neuroblastoma-likelihood-of-approval/ 2024-06-19T16:15:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elamipretide-hydrochloride-stealth-biotherapeutics-barth-syndrome-likelihood-of-approval/ 2025-01-21T17:07:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mw-189-immunochem-therapeutics-intracerebral-hemorrhage-likelihood-of-approval/ 2025-01-21T17:07:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval/ 2025-01-21T17:07:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T17:07:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-leiomyosarcoma-likelihood-of-approval/ 2025-01-21T17:07:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2025-01-21T17:07:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-neuroendocrine-carcinoma-likelihood-of-approval/ 2025-01-21T17:07:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-uterine-cancer-likelihood-of-approval/ 2025-01-21T17:07:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-chordoma-likelihood-of-approval/ 2025-01-21T17:06:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-gallbladder-cancer-likelihood-of-approval/ 2025-01-21T17:06:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-21T17:06:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-anaplastic-astrocytoma-likelihood-of-approval/ 2025-01-21T17:06:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-213-novabiotics-onychomycosis-tinea-unguium-likelihood-of-approval/ 2024-05-17T02:23:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-bladder-cancer-likelihood-of-approval/ 2025-01-21T17:06:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T17:06:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defactinib-hydrochloride-verastem-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:06:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fluocinolone-acetonide-sr-eyepoint-pharmaceuticals-retinopathy-likelihood-of-approval/ 2025-01-21T17:06:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibcasertib-shenzhen-chipscreen-biosciences-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T17:06:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guselkumab-johnson-johnson-skin-inflammation-likelihood-of-approval/ 2025-01-21T17:06:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritelivir-mesylate-aicuris-anti-infective-cures-simplexvirus-hsv-infections-likelihood-of-approval/ 2025-01-21T17:06:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zolbetuximab-astellas-pharma-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-21T17:06:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gimatecan-lee-s-pharmaceutical-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T06:03:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T17:06:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avacopan-amgen-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2025-01-21T17:06:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voruciclib-mei-pharma-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T16:14:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-precursor-b-cell-lymphoblastic-leukemia-lymphoma-likelihood-of-approval/ 2025-01-21T17:06:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voruciclib-mei-pharma-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T16:14:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voruciclib-mei-pharma-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T16:14:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voruciclib-mei-pharma-mantle-cell-lymphoma-likelihood-of-approval/ 2024-06-19T16:14:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voruciclib-mei-pharma-follicular-lymphoma-likelihood-of-approval/ 2024-06-19T16:14:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voruciclib-mei-pharma-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-06-19T16:14:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voruciclib-mei-pharma-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T16:14:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ep-0057-ellipses-pharma-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-21T17:06:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voruciclib-mei-pharma-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-06-19T16:14:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saroglitazar-zydus-therapeutics-metabolic-dysfunction-associated-steatotic-liver-disease-masld-likelihood-of-approval/ 2025-01-21T17:06:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bempedoic-acid-esperion-therapeutics-cardiovascular-disease-likelihood-of-approval/ 2025-01-21T17:06:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saroglitazar-zydus-therapeutics-cholestasis-likelihood-of-approval/ 2025-01-21T17:05:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saroglitazar-zydus-therapeutics-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-21T17:06:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saroglitazar-zydus-therapeutics-liver-diseases-likelihood-of-approval/ 2025-01-21T17:05:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saroglitazar-zydus-therapeutics-primary-sclerosing-cholangitis-likelihood-of-approval/ 2025-01-21T17:05:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saroglitazar-zydus-therapeutics-primary-biliary-cholangitis-primary-biliary-cirrhosis-likelihood-of-approval/ 2025-01-21T17:05:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atibuclimab-implicit-bioscience-cardiomyopathy-likelihood-of-approval/ 2025-01-21T17:05:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/narazaciclib-traws-pharma-endometrial-cancer-likelihood-of-approval/ 2025-01-21T17:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ronopterin-verinos-operations-traumatic-brain-injury-likelihood-of-approval/ 2024-05-17T02:13:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tecovirimat-siga-technologies-monkeypox-likelihood-of-approval/ 2024-06-19T16:13:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-ipsen-solid-tumor-likelihood-of-approval/ 2025-01-21T17:05:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/endostatin-simcere-pharmaceutical-group-malignant-pleural-effusion-likelihood-of-approval/ 2024-09-09T06:03:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelitolimod-sodium-trisalus-life-sciences-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T17:05:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/endostatin-simcere-pharmaceutical-group-ascites-likelihood-of-approval/ 2024-09-09T06:03:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelitolimod-sodium-trisalus-life-sciences-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-21T17:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-albumin-bound-aadi-bioscience-ovarian-cancer-likelihood-of-approval/ 2025-01-21T17:05:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-albumin-bound-aadi-bioscience-uterine-cancer-likelihood-of-approval/ 2025-01-21T17:05:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-ipsen-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval/ 2025-01-21T17:05:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thymalfasin-sciclone-pharmaceuticals-cystic-fibrosis-likelihood-of-approval/ 2025-01-21T17:05:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceftobiprole-medocaril-basilea-pharmaceutica-skin-and-skin-structure-infections-sssi-likelihood-of-approval/ 2025-01-21T17:05:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/everolimus-novartis-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2025-01-21T17:05:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceftobiprole-medocaril-basilea-pharmaceutica-methicillin-resistant-staphylococcus-aureus-mrsa-infections-likelihood-of-approval/ 2025-01-21T17:05:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceftobiprole-medocaril-basilea-pharmaceutica-methicillin-susceptible-staphylococcus-aureus-mssa-infections-likelihood-of-approval/ 2025-01-21T17:05:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceftobiprole-medocaril-basilea-pharmaceutica-sepsis-likelihood-of-approval/ 2025-01-21T17:05:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimavanserin-tartrate-acadia-pharmaceuticals-autism-spectrum-disorder-asd-likelihood-of-approval/ 2024-05-17T02:07:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tezepelumab-amgen-eosinophilic-esophagitis-likelihood-of-approval/ 2025-01-21T17:05:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bezisterim-biovie-alzheimer-s-disease-likelihood-of-approval/ 2025-01-21T17:04:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bezisterim-biovie-mild-cognitive-impairment-likelihood-of-approval/ 2025-01-21T17:04:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pepinemab-vaccinex-solid-tumor-likelihood-of-approval/ 2025-01-21T17:04:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pepinemab-vaccinex-osteosarcoma-likelihood-of-approval/ 2025-01-21T17:04:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-esophageal-cancer-likelihood-of-approval/ 2025-01-21T17:04:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:04:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-21T17:04:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizotinib-pfizer-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-21T17:04:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/canakinumab-novartis-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T17:04:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:04:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glycopyrrolate-novartis-asthma-likelihood-of-approval/ 2024-05-17T02:03:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:04:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tecarfarin-sodium-cadrenal-therapeutics-thrombosis-likelihood-of-approval/ 2024-07-05T18:31:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-21T17:04:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T17:04:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T17:04:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-thymic-carcinoma-likelihood-of-approval/ 2025-01-21T17:04:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T17:04:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-malignant-mesothelioma-likelihood-of-approval/ 2025-01-21T17:04:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mecasermin-rinfabate-oak-hill-bio-hemorrhage-likelihood-of-approval/ 2025-01-21T17:03:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:04:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annamycin-moleculin-biotech-liposarcoma-likelihood-of-approval/ 2024-09-09T06:02:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annamycin-moleculin-biotech-synovial-sarcoma-likelihood-of-approval/ 2024-09-09T06:02:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T17:03:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/annamycin-moleculin-biotech-angiosarcoma-likelihood-of-approval/ 2024-09-09T06:02:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vismodegib-genentech-usa-meningioma-likelihood-of-approval/ 2025-01-21T17:03:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vismodegib-genentech-usa-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-21T17:03:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cediranib-maleate-astrazeneca-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T17:03:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cediranib-maleate-astrazeneca-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T17:03:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zibotentan-astrazeneca-liver-cirrhosis-likelihood-of-approval/ 2024-07-05T18:31:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cediranib-maleate-astrazeneca-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:03:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/riociguat-bayer-sickle-cell-disease-likelihood-of-approval/ 2024-05-17T01:57:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-1656-conduit-pharmaceuticals-uveitis-likelihood-of-approval/ 2025-01-21T17:03:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-vaginal-cancer-likelihood-of-approval/ 2025-01-21T17:03:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-neuroendocrine-tumors-likelihood-of-approval/ 2025-01-21T17:03:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-uterine-cancer-likelihood-of-approval/ 2025-01-21T17:03:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-amgen-osteoarthritis-likelihood-of-approval/ 2025-01-21T17:03:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-21T17:03:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-gallbladder-cancer-likelihood-of-approval/ 2025-01-21T17:03:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/patient-access-to-medicines-must-be-the-focus-of-us-drug-pricing-policy/ 2024-05-16T20:21:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ionis-and-biogen-discontinue-experimental-als-drug-after-phase-i-ii-flop/ 2024-05-16T16:09:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/food-allergy-awareness-week-2024-how-can-new-treatments-target-an-unmet-need/ 2024-05-16T14:50:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uniquity-bio-launches-with-300m-and-an-msd-phase-ii-asset-to-boot/ 2024-05-16T14:54:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-targets-obesity-market-with-early-positive-trial-data/ 2024-05-16T14:32:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-new-target-benevolentai/ 2024-05-16T10:15:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/podcast-2-doing-digital-deals-in-life-sciences-information-governance-2/ 2024-05-16T09:15:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-dengue-vaccine-who/ 2024-05-16T08:36:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-bristol-myers-squibb-breyanzi/ 2024-05-16T08:35:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/kras-inhibitors-the-next-frontier-beckons/ 2024-05-15T17:21:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/tracking-the-opioid-lawsuit-settlements-amidst-calls-for-oversight/ 2024-05-15T20:25:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bhv-1300-biohaven-net-present-value/ 2024-07-02T02:15:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-131-crispr-therapeutics-net-present-value/ 2024-06-13T18:51:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-2051-cytomx-therapeutics-net-present-value/ 2024-07-02T02:15:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sys-6002-corbus-pharmaceuticals-net-present-value/ 2024-07-02T02:15:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fb-102-forte-biosciences-net-present-value/ 2024-05-16T01:50:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tn-401-tenaya-therapeutics-net-present-value/ 2024-05-16T01:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-net-present-value/ 2024-05-16T01:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-323-biontech-net-present-value/ 2024-12-13T02:54:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtx-2735-ventyx-biosciences-net-present-value/ 2024-06-13T18:51:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epinephrine-aquestive-therapeutics-net-present-value/ 2024-05-16T12:24:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgt-003-solid-biosciences-net-present-value/ 2024-07-02T02:15:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zidesamtinib-nuvalent-net-present-value/ 2024-06-13T18:51:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tak-861-takeda-pharmaceutical-net-present-value/ 2024-12-13T02:51:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iluzanebart-vigil-neuroscience-net-present-value/ 2024-06-13T18:51:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jzp-898-jazz-pharmaceuticals-net-present-value/ 2024-07-02T02:03:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cln-049-cullinan-therapeutics-net-present-value/ 2024-12-13T02:51:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cln-619-cullinan-therapeutics-net-present-value/ 2024-07-02T02:03:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anb-032-anaptysbio-net-present-value/ 2024-12-13T02:54:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aoc-1020-avidity-biosciences-net-present-value/ 2024-05-16T01:45:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-19-nkarta-net-present-value/ 2024-07-02T02:14:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/edg-7500-edgewise-therapeutics-net-present-value/ 2024-05-16T01:44:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inb-100-in8bio-net-present-value/ 2024-07-02T02:14:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inb-400-in8bio-net-present-value/ 2024-07-02T02:15:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tc-tlr7-8-ascendis-pharma-net-present-value/ 2024-07-02T02:14:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pr-006-eli-lilly-and-co-net-present-value/ 2024-07-02T02:14:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pl-9643-palatin-technologies-net-present-value/ 2024-05-16T01:42:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elritercept-keros-therapeutics-net-present-value/ 2024-07-02T02:03:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribitol-bridgebio-pharma-net-present-value/ 2024-07-02T02:14:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deucrictibant-immediate-release-pharvaris-net-present-value/ 2024-06-13T18:50:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdtx-1535-black-diamond-therapeutics-net-present-value/ 2024-07-02T02:14:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zelebrudomide-nurix-therapeutics-net-present-value/ 2024-06-13T18:50:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/barzolvolimab-celldex-therapeutics-net-present-value/ 2024-12-13T02:54:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/delpacibart-etedesiran-avidity-biosciences-net-present-value/ 2024-05-16T01:40:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fhd-286-foghorn-therapeutics-net-present-value/ 2024-05-16T01:39:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-compass-pathways-net-present-value/ 2024-05-16T01:38:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tpst-1120-tempest-therapeutics-net-present-value/ 2024-06-13T18:50:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1117568-neurocrine-biosciences-net-present-value/ 2024-05-16T01:38:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bepranemab-ucb-net-present-value/ 2024-12-13T02:54:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bbp-631-bridgebio-pharma-net-present-value/ 2024-07-02T02:03:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etalanetug-eisai-net-present-value/ 2024-12-13T02:54:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/casdozokitug-coherus-biosciences-net-present-value/ 2024-07-02T02:14:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sibeprenlimab-otsuka-net-present-value/ 2024-12-13T02:51:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-net-present-value/ 2024-07-02T02:14:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brepocitinib-tosylate-roivant-sciences-net-present-value/ 2024-06-13T18:50:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifileucel-iovance-biotherapeutics-net-present-value/ 2024-06-13T18:50:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nnv1-calidi-biotherapeutics-net-present-value/ 2024-07-02T02:14:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rebisufligene-etisparvovec-ultragenyx-pharmaceutical-net-present-value/ 2024-05-16T01:33:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jzp-815-jazz-pharmaceuticals-net-present-value/ 2024-06-13T18:50:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/centanafadine-otsuka-net-present-value/ 2024-07-02T02:02:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tinlarebant-belite-bio-net-present-value/ 2024-06-13T18:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tour-006-tourmaline-bio-net-present-value/ 2024-06-13T18:50:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/av-101-vistagen-therapeutics-net-present-value/ 2024-05-16T01:31:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/companies-prepare-for-adc-trial-readouts-at-asco-2024/ 2024-05-17T14:25:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eisai-begins-rolling-submission-to-fda-for-injectable-version-of-leqembi/ 2024-05-15T15:28:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-rejects-label-expansion-for-dynavaxs-hepatitis-b-vaccine/ 2024-05-15T15:24:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/glp-1-receptor-agonist-sales-125bn-2033/ 2024-05-15T14:33:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-clears-ind-for-verismo-therapeutics-car-t-therapy/ 2024-05-15T14:17:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/oct-europe-everyone-benefit-research/ 2024-05-15T10:59:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/university-of-nottingham-printed-medication/ 2024-05-15T10:41:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/enveric-psilocin-prodrug-mindbio/ 2024-05-15T10:09:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nabla-bio-series-a-funding/ 2024-05-15T08:22:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/circrna-vaccines-therapeutics-biomarkers-revolutionised/ 2024-05-15T08:36:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moffitt-fulgent-pharma-cancer-therapies/ 2024-05-15T08:59:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bayer-reports-drop-in-q1-sales-amidst-patent-litigation-challenges/ 2024-05-14T17:08:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/walden-biosciences-teams-up-with-primula-for-kidney-disease-study/ 2024-05-14T16:54:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-makes-psychedelic-play-with-2bn-gilgamesh-collaboration/ 2024-05-15T17:37:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cytokinetics-looks-to-take-on-bms-camzyos-in-hypertrophic-cardiomyopathy/ 2024-05-14T15:03:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ai-database-dandelion-health-glp1ra-precision-medicine/ 2024-05-14T11:08:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-biomanufacturing-investment-france/ 2024-05-14T10:45:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-opioid-overdose-treatment/ 2024-05-14T10:49:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pint-pharma-orladeyo-mexico/ 2024-05-14T09:00:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-pfizer-tafamidis-attr-cm/ 2024-05-14T08:53:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-and-zai-labs-augtyro-gains-nmpa-approval-to-treat-nsclc/ 2024-05-13T15:25:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-shells-out-100m-to-license-ac-immunes-phase-ii-alzheimers-therapy/ 2024-05-13T15:09:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dupixent-set-for-fda-review-in-adolescent-chronic-inflammatory-sinus-disease/ 2024-05-13T14:57:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-strikes-1bn-deal-with-fulcrum-for-muscular-dystrophy-drug/ 2024-05-13T14:56:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dementia-action-week-2024-the-future-of-alzheimers-diagnostics/ 2024-05-13T08:30:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/lulas-progress-plan-for-brazil-a-year-on/ 2024-05-10T19:27:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-signs-1bn-licensing-agreement-for-novavax-covid19-vaccine/ 2024-05-10T15:57:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rapt-terminates-phase-ii-trials-for-lead-candidate-following-clinical-hold/ 2024-05-10T15:56:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/freeline-touts-positive-data-for-gaucher-disease-therapy/ 2024-05-10T15:51:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/westgene-wins-fda-approval-for-mrna-vaccine-to-treat-certain-cancers/ 2024-05-28T18:00:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/shionogi-pompe-disease-treatment/ 2024-05-10T10:31:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/formosa-tabuk-ophthalmic-suspension/ 2024-05-14T05:07:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/four-ways-the-vaccine-rush-will-define-infectious-disease-trends-for-cros-in-2024/ 2025-02-18T14:34:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/attovia-105m-funds/ 2024-05-10T09:06:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-therapies-obesity/ 2024-05-10T09:04:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/marinus-parts-ways-with-20-of-its-workforce/ 2024-05-09T16:38:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-holdings-backed-commit-launches-with-17-2m-in-seed-funding/ 2024-05-09T16:04:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/acumen-doses-first-patient-in-phase-ii-alzheimers-disease-trial/ 2024-05-09T16:42:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-tackles-900m-restructuring-plan-after-generics-hurt-annual-profits/ 2024-05-09T14:11:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-growth-of-clinical-trials-in-africa/ 2025-07-15T12:29:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rakovina-expands-collaborations-to-leverage-ai-platform/ 2024-05-09T13:12:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ghit-fund-malaria-ntd-drug-development/ 2024-05-09T10:45:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dmu-surrey-epsrc/ 2024-05-09T10:44:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sobis-aspaveli-extension-europe/ 2024-05-09T08:37:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/anixa-cleveland-clinic-cancer-vaccine/ 2024-05-09T08:06:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/escmid-2024-emerging-bacterial-infections-in-neonates-and-children/ 2024-05-08T18:57:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biotechs-must-prioritise-ethics-to-deter-genai-bad-actors/ 2024-05-08T15:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/zenas-raises-200m-to-advance-autoimmune-antibody-therapy/ 2024-05-08T14:52:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-iecure-otc-deficiency-therapy-2/ 2024-05-08T10:08:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-withdraws-covid-vaccine/ 2024-05-08T10:12:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-six-trends-are-driving-pharmaceutical-milling/ 2024-05-08T09:16:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bioversys-gsk-tb-treatment/ 2024-05-08T08:14:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ter-sera-zoladex-la-health-canada/ 2024-05-08T08:34:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/broken-string-biosciences-teams-up-with-francis-crick-institute-for-als-research/ 2024-05-07T16:43:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/psilocybin-effective-in-treating-depression/ 2024-05-07T17:21:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vertex-reports-net-profits-of-2-69bn-in-q1-2024/ 2024-05-07T15:38:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biontech-net-loss-q1-2024/ 2024-05-07T10:14:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nmpa-breakthrough-therapy-innovent-ibi343/ 2024-05-07T10:28:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/awards/submissions-open-2/ 2024-06-13T21:55:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gossamer-bio-chiesi-pah/ 2024-05-07T08:36:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-equity-investment-cellectis/ 2024-05-07T08:24:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/how-sham-patents-are-hurting-the-pharma-industry/ 2024-06-07T18:59:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cipla-glenmark-recall-products/ 2024-05-06T10:11:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lantern-oregon-cancer-treatment/ 2024-05-06T10:07:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-viiv-cabotegravir-hiv/ 2024-05-06T08:03:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sentynl-acquires-eiger-zokinvy/ 2024-05-06T08:02:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amgen-reports-a-22-increase-in-q1-2024-net-revenues/ 2024-05-03T16:58:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/angle-signs-astrazeneca-deal-to-develop-prostate-cancer-assay/ 2024-05-03T16:04:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-grants-rmat-designation-to-tayshas-rett-syndrome-gene-therapy/ 2024-05-14T16:52:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lexicon-plans-another-bid-for-zynquista-in-type-1-diabetes/ 2024-05-03T14:38:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/escmid-2024-advances-in-drug-resistance-testing/ 2024-05-03T14:23:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-pfizer-voxelotor-sickle-cell-disease/ 2024-05-03T10:15:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bridgebio-oncology-therapeutics/ 2024-05-03T10:43:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/optimisation-in-operations-from-theory-to-practice/ 2024-05-03T08:56:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-net-loss-q1-2024/ 2024-05-03T08:34:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immunitybio-serum-institute-bcg/ 2024-05-03T08:35:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/escmid-2024-drug-resistance-in-fungi-a-growing-issue/ 2024-05-02T18:39:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-aims-for-market-domination-boasts-1-5bn-obesity-sales-in-q1/ 2024-05-02T16:26:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-acquires-mariana-in-1-75bn-deal-to-strengthen-radioligand-portfolio/ 2024-05-02T15:20:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biotechs-face-upward-battle-with-recruiting-patients-on-obesity-trials/ 2025-03-12T19:26:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/emergent-cuts-300-jobs-and-shuts-down-two-facilities-in-cost-cutting-drive/ 2024-05-02T14:52:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ma-revival-deals-q1-2024/ 2024-05-02T14:49:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vertex-pharmaceuticals-gets-grant-for-treatment-of-alpha-1-antitrypsin-deficiency-with-compound-of-formula-i/ 2024-05-02T13:04:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biocryst-pharmaceuticals-gets-grant-for-inhibitors-of-the-complement-system-for-disease-treatment/ 2024-05-02T13:04:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astellas-pharma-gets-grant-for-novel-carbocyclic-prolinamide-derivatives-for-treating-age-related-macular-degeneration/ 2024-05-02T13:04:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agenus-gets-grant-for-monoclonal-antibodies-targeting-tim-3-for-treating-subjects/ 2024-05-02T13:03:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/macrogenics-gets-grant-for-patent-granted-for-compounds-targeting-il23a-and-baff/ 2024-05-02T13:03:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/janssen-cilag-ema-tremfya/ 2024-05-02T10:29:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/xyphos-poseida-cell-therapies-cancer/ 2024-12-18T10:35:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-boehringer-cyltezo-approval/ 2024-09-17T20:54:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-net-income-q1/ 2024-05-02T08:23:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/the-top-pharmaceutical-companies-by-rd-expenditure/ 2024-05-01T09:47:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/magazine-anticipation-rises-for-rsv-rollout-as-positive-data-emerges/ 2024-05-01T16:46:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/adc-chinese-companies-pipeline/ 2024-05-01T16:14:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-admits-covid-19-vaccine-may-cause-blood-clots-in-very-rare-cases/ 2024-05-01T15:45:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/neurocrine-bags-fda-approval-for-new-sprinkle-ingrezza-formulation/ 2024-05-01T15:06:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/janssen-adopts-jj-name-as-part-of-global-rebranding-effort/ 2024-05-01T14:51:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/replay-wins-ind-clearance-for-prame-t-cell-cancer-therapy/ 2024-05-01T14:45:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/epro-vs-ecoa-understanding-the-nuances-in-clinical-trials/ 2024-05-01T11:14:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/roche-vabysmo-successful-q1-sales/ 2024-05-01T10:31:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/enlaza-series-a-funding/ 2024-05-01T10:08:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bayer-evotec-cardiology-therapeutics/ 2024-05-01T10:18:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-q1-net-income/ 2024-05-01T08:28:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-peptidream-peptide-deal/ 2024-05-01T07:48:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-in-cloud-theme-innovation-strategy/ 2024-05-23T13:05:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-in-advanced-materials-theme-innovation-strategy/ 2024-05-23T13:05:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/memorial-sloan-kettering-cancer-center-in-big-data-theme-innovation-strategy/ 2024-05-23T13:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-in-robotics-theme-innovation-strategy-2/ 2024-05-23T13:03:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-in-future-of-work-theme-innovation-strategy/ 2024-08-01T06:12:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/memorial-sloan-kettering-cancer-center-in-3d-printing-theme-innovation-strategy/ 2024-05-23T13:05:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-advanced-materials-theme-innovation-strategy-2/ 2024-05-23T13:03:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-in-digitalization-theme-innovation-strategy/ 2024-08-01T06:12:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-in-internet-of-things-theme-innovation-strategy/ 2024-05-23T13:03:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-robotics-theme-innovation-strategy-2/ 2024-05-23T13:02:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-future-of-work-theme-innovation-strategy-2/ 2024-05-23T13:02:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-ecommerce-theme-innovation-strategy/ 2024-05-23T13:03:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-digitalization-theme-innovation-strategy-2/ 2024-05-23T13:02:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-internet-of-things-theme-innovation-strategy-2/ 2024-05-23T13:02:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-mobile-theme-innovation-strategy-2/ 2024-05-23T13:02:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amgen-in-robotics-theme-innovation-strategy-2/ 2024-05-23T13:01:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amgen-in-future-of-work-theme-innovation-strategy-2/ 2024-05-23T13:02:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-big-data-theme-innovation-strategy-2/ 2024-05-23T13:02:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-cybersecurity-theme-innovation-strategy-3/ 2024-05-23T13:01:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-in-artificial-intelligence-theme-innovation-strategy-3/ 2024-05-23T13:01:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/memorial-sloan-kettering-cancer-center-in-artificial-intelligence-theme-innovation-strategy-3/ 2024-05-23T13:01:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azenta-in-robotics-theme-innovation-strategy-2/ 2024-05-23T13:00:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amgen-in-artificial-intelligence-theme-innovation-strategy-3/ 2024-05-23T13:01:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-in-artificial-intelligence-theme-innovation-strategy-3/ 2024-05-23T13:01:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/escmid-2024-the-infectious-consequences-of-climate-change/ 2024-04-30T16:53:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-and-genmabs-tivdak-wins-full-fda-approval-for-cervical-cancer/ 2024-11-06T10:16:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ionis-pharmaceuticals-gets-grant-for-modified-oligonucleotide-for-reducing-lrrk2-rna-in-neurodegenerative-diseases/ 2024-04-30T12:47:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/precision-biosciences-gets-grant-for-engineered-meganucleases-for-modifying-human-mitochondrial-dna/ 2024-04-30T12:47:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/corcept-therapeutics-gets-grant-for-method-of-preparing-compound-of-formula-i/ 2024-04-30T12:46:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/merus-gets-grant-for-treatment-of-clec12a-positive-cancer-with-bispecific-antibody/ 2024-04-30T12:46:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacira-biosciences-gets-grant-for-method-for-treating-spasticity-in-a-patient-s-limb-using-cryogenic-cooling/ 2024-04-30T12:46:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inovio-pharmaceuticals-gets-grant-for-electroporation-device-with-adjustable-needle-array-auto-lock-assembly/ 2024-04-30T12:46:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eyepoint-pharmaceuticals-gets-grant-for-treatment-of-ocular-conditions-with-multi-specific-compounds/ 2024-04-30T12:45:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axsome-therapeutics-gets-grant-for-treating-narcolepsy-with-cataplexy-using-reboxetine/ 2024-04-30T12:45:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligand-pharmaceuticals-gets-grant-for-imidazole-fused-heterocycle-compounds-for-treating-leukemia/ 2024-04-30T12:45:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alnylam-pharmaceuticals-gets-grant-for-inhibiting-expression-of-serum-amyloid-a-gene/ 2024-04-30T12:45:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/supernus-pharmaceuticals-gets-grant-for-extended-release-amantadine-tablet-for-treating-neurological-disorders/ 2024-04-30T12:44:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/santen-pharmaceutical-gets-grant-for-monoclonal-antibody-with-high-affinity-for-vegf/ 2024-04-30T12:44:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anges-gets-grant-for-rna-molecules-for-inactivating-mutant-best1-allele/ 2024-04-30T12:44:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/intas-pharmaceuticals-gets-grant-for-extended-release-pharmaceutical-composition-of-clozapine-in-multiparticulates/ 2024-04-30T12:44:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellectis-gets-grant-for-genetic-insertion-in-immune-cells-to-target-infected-cells/ 2024-04-30T12:43:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enzo-biochem-gets-grant-for-method-for-detecting-enzymes-adding-functional-groups-to-compounds/ 2024-04-30T12:43:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biogen-gets-grant-for-compounds-of-formula-i-for-pharmaceutical-use/ 2024-04-30T12:43:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vanda-pharmaceuticals-gets-grant-for-use-of-melatonin-agonist-tasimelteon-in-treating-circadian-rhythms/ 2024-04-30T12:42:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deciphera-pharmaceuticals-gets-grant-for-pharmaceutical-composition-for-treating-disorders-related-to-kinase-activity/ 2024-04-30T12:42:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amicus-therapeutics-gets-grant-for-treating-fabry-disease-using-pharmacological-chaperones-for-a-galactosidase-a/ 2024-04-30T12:42:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-pharmaceutical-gets-grant-for-compound-for-treating-disorders-associated-with-trek-1-and-trek-2-dysfunction/ 2024-04-30T12:42:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/organovo-gets-grant-for-3d-bioprinted-renal-tissue-for-assessing-renal-toxicity-of-agents/ 2024-04-30T12:41:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/codexis-gets-grant-for-engineered-deoxyribose-phosphate-aldolase-for-pharmaceutical-and-fine-chemicals/ 2024-04-30T12:41:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hisamitsu-pharmaceutical-gets-grant-for-gel-patch-for-pain-relief-with-specific-ingredients/ 2024-04-30T12:41:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azenta-gets-grant-for-ice-lined-vaccine-refrigerator-with-dc-powered-compressor/ 2024-04-30T12:41:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aurobindo-pharma-gets-grant-for-stable-pharmaceutical-composition-of-amorphous-canagliflozin/ 2024-04-30T12:40:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biontech-gets-grant-for-screening-for-genotype-loss-of-antigen-presentation-via-mhc-class-i/ 2024-04-30T12:40:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaccinex-gets-grant-for-antibodies-binding-human-ccr8-for-treating-diseases-2/ 2024-04-30T12:40:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amgen-gets-grant-for-bispecific-antibody-for-human-cgrp-and-pac1-receptors/ 2024-04-30T12:40:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/altimmune-gets-grant-for-pharmaceutical-composition-of-peptides-for-hbv-treatment/ 2024-04-30T12:39:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vertex-pharmaceuticals-gets-grant-for-feeder-free-culture-of-primate-pluripotent-stem-cells/ 2024-04-30T12:39:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anavex-life-sciences-gets-grant-for-treatment-prevention-of-pain-using-av1066-dosage-form/ 2024-04-30T12:39:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chmp-astrazenecas-truqap-faslodex/ 2024-04-30T10:31:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/accord-biopharma-hercessi-fda/ 2024-04-30T10:20:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/addex-stock-tanks-after-lead-drug-flops-in-phase-ii-epilepsy-trial/ 2024-04-30T13:27:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/repertoire-bristol-vaccines/ 2024-04-30T08:46:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-x4-syndrome-drug/ 2024-04-30T08:21:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ono-pharmaceutical-acquires-cancer-focused-biopharma-deciphera-for-2-4bn/ 2024-04-30T09:37:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biodexa-gains-license-for-polyposis-asset-as-stock-more-than-doubles/ 2024-04-29T16:15:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/profound-concern-over-whos-pandemic-agreement-says-aids-charity/ 2024-04-29T15:18:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/astrazeneca-fasenra-copd-approval/ 2024-04-29T15:13:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/biosecure-bill-targets-more-chinese-companies-as-biotechs-and-their-customers-adapt-to-defunding/ 2024-05-02T20:14:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/duchenne-muscular-dystrophy-the-global-clinical-trials-landscape-2024/ 2024-04-29T11:00:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sino-biological-signalchem-48m/ 2024-04-29T10:35:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pharmalink-recall-results-drugs/ 2024-04-29T10:30:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-expands-fda-label-for-biktarvy-with-phase-i-pregnant-hiv-patient-data/ 2024-04-29T13:52:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pierre-fabres-vibegron/ 2024-04-29T09:13:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-fda-haemophilia-b/ 2024-05-01T08:33:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/cell-and-gene-therapy-companies-trip-at-scalability-hurdle/ 2024-05-08T09:26:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/escmid-2024-using-ai-in-infection-prevention-and-control/ 2024-04-29T00:25:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pioneer-institute-study-finds-ira-discourages-non-opioid-drug-innovation/ 2024-04-26T16:19:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/the-privileged-status-of-orphan-medicines-in-germany/ 2024-04-26T14:48:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/top-20-biopharma-kick-off-market-cap-surge-q1-2024/ 2024-04-26T14:42:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cerevance-raises-47m-to-fund-phase-iii-trial-for-lead-parkinsons-therapy/ 2024-04-26T14:56:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mercks-net-income-2024/ 2024-04-26T10:52:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/multiply-genscript-cell-isolation/ 2024-05-01T08:33:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/regeneron-mammoth-therapies/ 2024-05-01T08:33:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-q1-2024-filings/ 2024-04-26T08:45:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanders-takes-aim-at-us-drug-prices-of-novos-ozempic-and-wegovy/ 2024-04-25T19:45:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cidara-buys-back-rights-to-flu-therapy-from-jj-for-85m/ 2024-09-13T11:33:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/inflation-reduction-act-to-have-knock-on-effect-on-rd-say-biotech-experts/ 2024-04-25T16:14:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/digital-deals-in-life-sciences-podcast-corporate-culture/ 2025-03-28T16:02:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-german-research-centre/ 2024-04-25T10:41:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mundipharma-rezafungin-cidara/ 2024-04-25T10:40:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/life-science-smes-heading-out-of-the-funding-winter/ 2024-04-25T08:29:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biogen-filings-q1-2024/ 2024-04-25T09:07:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-fda-therapeutics-pivya/ 2024-04-25T09:06:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/investors-anticipate-bounce-back-in-european-private-investment/ 2025-03-12T19:20:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-bags-paediatric-fda-label-expansion-for-lutathera/ 2024-04-24T15:38:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/johnson-johnson-gets-grant-for-heart-ultrasound-image-selection-based-on-physiological-cycle/ 2024-04-25T09:14:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pfizer-gets-grant-for-treatment-of-cancer-using-engineered-immune-cells-targeting-bcma/ 2024-04-24T13:18:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bicycle-therapeutics-gets-grant-for-high-affinity-binders-of-nectin-4-for-treating-diseases/ 2024-04-24T13:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viatris-gets-grant-for-nasal-spray-method-for-treating-dry-eye-disease/ 2024-04-24T13:18:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sanofi-gets-grant-for-optical-decoding-system-for-determining-medicament-dose-in-drug-delivery-device/ 2024-04-24T13:18:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apellis-pharmaceuticals-gets-grant-for-treatment-of-complement-mediated-eye-disorder-with-long-acting-compstatin-analog/ 2024-04-24T13:17:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipsen-gets-grant-for-treatment-of-diseases-with-specific-benzothiazepine-and-benzothiadiazepine-derivatives/ 2024-04-24T13:17:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seres-therapeutics-gets-grant-for-composition-of-isolated-bacteria-in-capsule-for-dysbiosis-treatment/ 2024-04-24T13:17:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biocryst-pharmaceuticals-gets-grant-for-inhibitors-of-the-complement-system-for-disease-treatment-2/ 2024-04-24T13:16:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/macrogenics-gets-grant-for-patent-granted-for-compounds-targeting-il23a-and-baff-2/ 2024-04-24T13:16:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astellas-pharma-gets-grant-for-antibodies-for-diagnosing-cancer-by-detecting-cldn6-expression/ 2024-04-24T13:16:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spectrum-pharmaceuticals-gets-grant-for-crystalline-form-of-quinazoline-compound-and-hydrochloride-salts-2/ 2024-04-24T13:16:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revance-therapeutics-gets-grant-for-stabilized-botulinum-toxin-formulation-without-protein-excipients/ 2024-04-24T13:15:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ionis-pharmaceuticals-gets-grant-for-modified-oligonucleotide-for-reducing-lrrk2-rna-in-neurodegenerative-diseases-2/ 2024-04-24T13:15:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/precision-biosciences-gets-grant-for-engineered-meganucleases-for-modifying-human-mitochondrial-dna-2/ 2024-04-24T13:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/corcept-therapeutics-gets-grant-for-treating-antipsychotic-induced-weight-gain-with-miricorilant/ 2024-04-24T13:15:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacira-biosciences-gets-grant-for-method-of-reducing-non-opioid-analgesic-post-hip-treatment/ 2024-04-24T13:14:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inovio-pharmaceuticals-gets-grant-for-electroporation-device-with-adjustable-needle-array-auto-lock-assembly-2/ 2024-04-24T13:14:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/merus-gets-grant-for-treatment-of-clec12a-positive-cancer-with-bispecific-antibody-2/ 2024-04-24T13:14:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axsome-therapeutics-gets-grant-for-treating-narcolepsy-with-cataplexy-using-reboxetine-2/ 2024-04-24T13:14:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligand-pharmaceuticals-gets-grant-for-imidazole-fused-heterocycle-compounds-for-treating-leukemia-2/ 2024-04-24T13:13:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bavarian-nordic-gets-grant-for-vaccine-for-protective-immunity-against-filovirus-infection/ 2024-04-24T13:13:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/supernus-pharmaceuticals-gets-grant-for-patent-granted-for-compound-of-formula-ii-for-cns-disorders/ 2024-04-24T13:13:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/santen-pharmaceutical-gets-grant-for-monoclonal-antibody-with-high-affinity-for-vegf-2/ 2024-04-24T13:13:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eyepoint-pharmaceuticals-gets-grant-for-treatment-of-ocular-conditions-using-multi-specific-compounds/ 2024-04-24T13:12:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ascendis-pharma-gets-grant-for-controlled-release-parathyroid-hormone-conjugate-for-medical-treatment/ 2024-04-24T13:12:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alnylam-pharmaceuticals-gets-grant-for-novel-cationic-lipids-for-lipid-nanoparticles-with-oligonucleotides/ 2024-04-24T13:12:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/intas-pharmaceuticals-gets-grant-for-extended-release-formulation-of-clozapine-with-improved-stability/ 2024-04-24T13:12:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enzo-biochem-gets-grant-for-method-for-detecting-enzymes-adding-functional-groups-to-compounds-2/ 2024-04-24T13:11:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vanda-pharmaceuticals-gets-grant-for-treatment-of-circadian-rhythm-disorder-using-tasimelteon/ 2024-04-24T13:11:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-pharmaceutical-gets-grant-for-compound-for-treating-cancer-or-infectious-disease/ 2024-04-24T13:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/organovo-gets-grant-for-bioprinted-renal-tissue-for-assessing-renal-toxicity-of-therapeutic-agents/ 2024-04-24T13:11:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sarepta-therapeutics-gets-grant-for-antisense-oligomers-for-treating-dystrophic-epidermolysis-bullosa/ 2024-04-24T13:10:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amicus-therapeutics-gets-grant-for-treatment-of-fabry-disease-with-migalastat-for-specific-mutations/ 2024-04-24T13:10:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/united-therapeutics-gets-grant-for-apparatus-for-pancreatic-function-restoration-using-membrane-with-cell-systems/ 2024-04-24T13:10:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hca-healthcare-gets-grant-for-adjustable-motion-sensing-outdoor-security-light/ 2024-04-24T13:09:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incyte-gets-grant-for-compound-for-treating-autoimmune-diseases-cancer-cardiovascular-and-neurodegenerative-diseases/ 2024-04-24T13:09:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chiesi-farmaceutici-gets-grant-for-oral-octreotide-therapy-method-for-females-needing-contraception/ 2024-04-24T13:09:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-gets-grant-for-method-for-generating-module-to-determine-analyte-concentration-in-body-fluid/ 2024-04-24T13:09:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grifols-gets-grant-for-fusion-proteins-for-monitoring-biotherapeutic-antibodies-in-immunoassays/ 2024-04-24T13:08:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zoetis-gets-grant-for-vaccine-for-protecting-porcine-animals-from-prrs-virus/ 2024-04-24T13:08:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shionogi-gets-grant-for-solid-dosage-form-with-good-stability-suspensibility-and-fluidity/ 2024-04-24T13:08:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esteve-pharmaceuticals-gets-grant-for-aids-prevention-and-treatment-vaccine-using-novel-immunogens/ 2024-04-24T13:08:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/intra-cellular-therapies-gets-grant-for-patent-granted-for-amorphous-solid-dispersion-of-iti-007-tosylate-salt/ 2024-04-24T13:07:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mannkind-gets-grant-for-dry-powder-composition-for-pulmonary-delivery-of-pde5-inhibitor-2/ 2024-04-24T13:07:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xencor-gets-grant-for-heterodimeric-antibody-binding-psma-and-cd3-for-cancer-treatment/ 2024-04-24T13:07:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deciphera-pharmaceuticals-gets-grant-for-pharmaceutical-composition-for-treating-disorders-related-to-c-kit-activity/ 2024-04-24T13:07:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellectis-gets-grant-for-chimeric-antigen-receptor-car-for-cd123-positive-cancer-treatment/ 2024-04-24T13:06:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biogen-gets-grant-for-treatment-of-disorders-responsive-to-ask1-inhibition/ 2024-04-24T13:06:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/gsk-lundbeck-rovi-three-journeys-of-unified-pharma-events-management/ 2024-04-29T16:21:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-astellas-xtandi-cancer/ 2024-04-24T10:56:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/incyte-escient-pharmaceuticals/ 2024-04-24T10:58:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-biontech-legal-uk/ 2024-04-24T08:19:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-net-income-2024/ 2024-04-24T07:58:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/social-prescribing-friend-or-foe-for-pharma/ 2024-05-02T15:45:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hepion-shelves-phase-ii-nash-trial-amid-shallow-cash-resources/ 2024-04-23T19:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/investors-advocate-for-early-biotech-partnerships-for-later-deal-success/ 2024-04-23T17:21:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/smaller-regulators-grasp-innovation-through-international-collaboration/ 2025-03-12T19:26:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/targeting-mouth-cancer-with-light-activated-drugs/ 2024-04-23T16:17:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-approves-beigenes-tislelizumab-for-three-nsclc-indications/ 2024-04-24T15:03:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/moderna-gets-grant-for-vaccine-composition-for-varicella-zoster-virus/ 2024-04-23T12:59:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bristol-myers-squibb-gets-grant-for-humanized-antibodies-binding-cd40-for-treatment-of-cd40-related-diseases/ 2024-04-23T12:59:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-gets-grant-for-herbicide-composition-with-glyphosate-amidoalkylamine-surfactant-and-co-surfactant/ 2024-04-23T12:58:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astrazeneca-gets-grant-for-inhibitors-of-complement-factor-d-for-treating-disorders/ 2024-04-23T12:58:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insmed-gets-grant-for-treatment-of-gram-positive-pulmonary-bacterial-infections-2/ 2024-04-23T12:58:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omeros-gets-grant-for-treating-diffuse-alveolar-hemorrhage-with-masp-2-inhibitory-antibody/ 2024-04-23T12:57:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sangamo-therapeutics-gets-grant-for-non-naturally-occurring-nucleases-with-alternative-configurations/ 2024-04-23T12:57:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/takara-gets-grant-for-selective-separation-of-target-nucleic-acids-from-a-composition-2/ 2024-04-23T12:57:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mimedx-group-gets-grant-for-amniotic-fluid-compositions-kit-with-administration-device/ 2024-04-23T12:57:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mallinckrodt-gets-grant-for-filter-apparatus-for-liquid-removal-from-gas/ 2024-04-23T12:56:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bausch-health-gets-grant-for-drug-delivery-method-using-polyphosphazene-drug-conjugates/ 2024-04-23T12:56:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/takeda-pharmaceutical-gets-grant-for-filling-system-for-stable-fluid-interface-in-filling-nozzle/ 2024-04-23T12:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/puretech-health-gets-grant-for-treatment-of-acute-myeloid-leukemia-using-genetically-engineered-cells/ 2024-04-23T12:56:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/codexis-gets-grant-for-engineered-acyltransferase-for-synthesizing-statin-compounds/ 2024-04-23T12:55:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lonza-group-gets-grant-for-nozzle-assembly-for-robust-spray-drying-system/ 2024-04-23T12:55:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-menarini-industrie-farmaceutiche-riunite-gets-grant-for-optical-analysis-of-particles-in-suspension-in-a-microchamber/ 2024-04-23T12:55:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gilead-sciences-gets-grant-for-treatment-of-viral-infections-with-compounds-and-salts/ 2024-04-23T12:55:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jubilant-pharmova-gets-grant-for-radiopharmaceutical-composition-for-diagnostic-imaging-with-stable-attributes-2/ 2024-04-23T12:54:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/merck-gets-grant-for-fast-disintegrating-tablet-with-compound-of-formula-ia/ 2024-04-23T12:54:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pathai-gets-grant-for-validating-performance-of-a-trained-model-for-pathology-images/ 2024-04-23T12:54:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/praxis-precision-medicines-gets-grant-for-treatment-of-neurological-disorders-with-fused-heteroaryl-compounds/ 2024-04-23T12:54:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/singular-genomics-systems-gets-grant-for-method-of-preparing-and-sequencing-double-stranded-polynucleotide-regions/ 2024-04-23T12:53:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kymera-therapeutics-gets-grant-for-treatment-of-crbn-mediated-disorders-using-specific-compounds/ 2024-04-23T12:53:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sutro-biopharma-gets-grant-for-hemiasterlin-derivatives-for-treating-cell-proliferation-and-cancer/ 2024-04-23T12:53:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/endo-international-gets-grant-for-patent-granted-for-recombinant-nucleic-acid-encoding-collagenase-2/ 2024-04-23T12:53:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acura-pharmaceuticals-gets-grant-for-abuse-deterrent-pharmaceutical-composition-with-delayed-release-mechanism-2/ 2024-04-23T12:52:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/heron-therapeutics-gets-grant-for-patent-granted-for-injectable-emulsion-to-prevent-post-operative-nausea/ 2024-04-23T12:52:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zevra-therapeutics-gets-grant-for-crystalline-form-of-emetine-dihydrochloride-2/ 2024-04-23T12:52:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glycomimetics-gets-grant-for-treatment-and-prevention-of-diseases-by-inhibiting-e-selectin-binding-2/ 2024-04-23T12:52:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/akebia-therapeutics-gets-grant-for-treating-anemia-with-specific-doses-of-hif-prolyl-hydroxylase-inhibitor-2/ 2024-04-23T12:51:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kinnate-biopharma-gets-grant-for-patent-granted-for-cancer-treatment-using-raf-inhibitor/ 2024-04-23T12:51:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blueprint-medicines-gets-grant-for-treatment-of-ret-altered-non-small-cell-lung-cancer-2/ 2024-04-23T12:51:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dyne-therapeutics-gets-grant-for-patent-granted-for-method-of-reducing-dmpk-expression-in-muscle/ 2024-04-23T12:51:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allogene-therapeutics-gets-grant-for-patent-granted-for-cd19-specific-cars-resistant-to-rituximab/ 2024-04-23T12:50:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krystal-biotech-gets-grant-for-pharmaceutical-composition-for-cancer-treatment-using-recombinant-hsv-1-virus/ 2024-04-23T12:50:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/redx-pharma-gets-grant-for-rock-inhibitors-for-treating-rock-mediated-diseases-2/ 2024-04-23T12:50:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ucb-gets-grant-for-dual-specific-il-17a-and-il-17f-antibody-for-therapy/ 2024-04-23T12:49:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mochida-pharmaceutical-gets-grant-for-self-emulsifying-preparation-for-enhanced-epa-absorption/ 2024-04-23T12:49:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yuhan-gets-grant-for-patent-granted-for-anti-pd-l1-igg-class-antibodies/ 2024-04-23T12:49:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/novartis-gets-grant-for-chimeric-antigen-receptor-for-t-cell-specificity-regulation/ 2024-04-23T12:49:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jazz-pharmaceuticals-gets-grant-for-cbd-preparation-with-at-least-90-cbd-and-thc-2/ 2024-04-23T12:48:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hanmi-science-gets-grant-for-compound-for-binding-to-globulin-fc-region-or-polypeptide/ 2024-04-23T12:48:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bioatla-gets-grant-for-patent-granted-for-antibody-binding-to-axl-protein/ 2024-04-23T12:48:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glenmark-pharmaceuticals-gets-grant-for-hetero-dimeric-immunoglobulins-for-binding-cd3-and-disease-antigens/ 2024-04-23T12:48:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sage-therapeutics-gets-grant-for-treatment-of-cns-related-conditions-using-compound-of-formula-b/ 2024-04-23T12:47:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regeneron-pharmaceuticals-gets-grant-for-treatment-of-non-small-cell-lung-cancer-with-pd-1-antagonist/ 2024-04-23T12:47:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jiangsu-hengrui-medicine-gets-grant-for-combination-of-anti-pd-1-antibody-and-vegfr-inhibitor-for-cancer-treatment-2/ 2024-04-23T12:47:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daiichi-sankyo-gets-grant-for-peptide-binding-to-active-mmp-9-not-pro-mmp-9/ 2024-04-23T12:47:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cytomx-therapeutics-gets-grant-for-activatable-antibody-for-treating-cancer-associated-with-egfr/ 2024-04-23T12:46:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbvie-gets-grant-for-inhibitors-of-menin-mll-interaction-for-cancer-treatment/ 2024-04-23T12:46:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ochre-bio-boehringer-regenerative-therapy/ 2024-04-23T10:35:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immunitybio-anktiva-fda-approval/ 2024-04-23T10:36:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-gears-up-for-approval-of-its-btk-inhibitor-meets-phase-iii-endpoint/ 2024-04-23T13:27:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ipsen-skyhawk-neurological-therapies/ 2024-04-23T09:01:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-pfizer-emblaveo-approval/ 2024-04-23T09:00:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/farletuzumab-ecteribulin-eisai-ovarian-cancer-likelihood-of-approval/ 2025-01-21T17:03:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lorcaserin-hydrochloride-epygenix-therapeutics-dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-likelihood-of-approval/ 2024-04-23T04:07:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alphamedix-orano-med-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval/ 2025-01-21T17:03:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T17:02:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-21T17:02:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-peritoneal-cancer-likelihood-of-approval/ 2025-01-21T17:02:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-21T17:02:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-21T17:02:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-21T17:02:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2025-01-21T17:02:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T17:02:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-21T17:02:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-esophageal-cancer-likelihood-of-approval/ 2025-01-21T17:02:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T17:02:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-endometrial-cancer-likelihood-of-approval/ 2025-01-21T17:02:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-cervical-cancer-likelihood-of-approval/ 2025-01-21T17:01:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:02:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/risvodetinib-succinate-inhibikase-therapeutics-constipation-likelihood-of-approval/ 2024-04-23T04:03:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/risvodetinib-succinate-inhibikase-therapeutics-dysphagia-likelihood-of-approval/ 2024-04-23T04:03:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dfp-14927-delta-fly-pharma-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-21T17:01:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-1718-bicycle-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T06:00:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dfp-14927-delta-fly-pharma-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T17:01:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dfp-14927-delta-fly-pharma-solid-tumor-likelihood-of-approval/ 2025-01-21T17:01:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaccine-for-oncology-cas-lamvac-biotech-prostate-cancer-likelihood-of-approval/ 2024-04-23T04:01:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-solid-tumor-likelihood-of-approval/ 2025-01-21T17:01:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tac-100-triumvira-immunologics-esophageal-cancer-likelihood-of-approval/ 2024-07-05T18:29:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tac-100-triumvira-immunologics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-07-05T18:29:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-rapt-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-23T04:00:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-rapt-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-04-23T04:00:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vopikitug-f-hoffmann-la-roche-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-23T04:00:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vopikitug-f-hoffmann-la-roche-esophageal-cancer-likelihood-of-approval/ 2024-04-23T04:00:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vopikitug-f-hoffmann-la-roche-head-and-neck-cancer-likelihood-of-approval/ 2024-04-23T03:59:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vopikitug-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2024-04-23T03:59:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vopikitug-f-hoffmann-la-roche-breast-cancer-likelihood-of-approval/ 2024-04-23T03:59:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vopikitug-f-hoffmann-la-roche-ovarian-cancer-likelihood-of-approval/ 2024-04-23T03:59:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-07-05T18:29:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-22T13:56:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-211-biontech-fallopian-tube-cancer-likelihood-of-approval/ 2024-07-05T18:29:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-211-biontech-peritoneal-tumor-likelihood-of-approval/ 2024-07-05T18:29:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-211-biontech-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:28:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-211-biontech-uterine-cancer-likelihood-of-approval/ 2024-07-05T18:28:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-211-biontech-sarcomas-likelihood-of-approval/ 2024-07-05T18:28:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-211-biontech-endometrial-cancer-likelihood-of-approval/ 2024-07-05T18:28:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-211-biontech-ovarian-cancer-likelihood-of-approval/ 2024-07-05T18:28:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-211-biontech-gastric-cancer-likelihood-of-approval/ 2024-07-05T18:28:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grn-300-greenfire-bio-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-04-23T03:55:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/renizgamglogene-autogedtemcel-editas-medicine-sickle-cell-disease-likelihood-of-approval/ 2025-01-21T17:01:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grn-300-greenfire-bio-prostate-cancer-likelihood-of-approval/ 2024-05-20T05:44:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grn-300-greenfire-bio-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-04-23T03:55:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naporafenib-erasca-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T17:00:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naporafenib-erasca-solid-tumor-likelihood-of-approval/ 2025-01-21T17:00:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belzutifan-merck-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-21T17:00:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-gastric-cancer-likelihood-of-approval/ 2025-01-21T17:00:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nms-088-nerviano-medical-sciences-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T16:08:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sintilimab-innovent-biologics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T17:00:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T17:00:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nms-088-nerviano-medical-sciences-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T16:08:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbm-c30-1-abelzeta-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T05:59:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lti-01-aileron-therapeutics-empyema-likelihood-of-approval/ 2024-04-23T03:52:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cisplatin-vinblastine-sulphate-intensity-therapeutics-leiomyosarcoma-likelihood-of-approval/ 2025-01-21T16:59:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cisplatin-vinblastine-sulphate-intensity-therapeutics-pleomorphic-liposarcoma-likelihood-of-approval/ 2025-01-21T17:00:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maplirpacept-pfizer-refractory-multiple-myeloma-likelihood-of-approval/ 2024-04-23T03:51:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talabostat-bioxcel-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T16:59:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-gastric-cancer-likelihood-of-approval/ 2025-01-21T16:59:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tuparstobart-incyte-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-09-09T05:59:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tislelizumab-beigene-androgen-sensitive-prostate-cancer-likelihood-of-approval/ 2024-09-09T05:59:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tislelizumab-beigene-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-09-09T05:59:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6631-f-hoffmann-la-roche-ulcerative-colitis-likelihood-of-approval/ 2025-01-21T16:59:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/histamine-dihydrochloride-agonex-biopharmaceuticals-alzheimer-s-disease-likelihood-of-approval/ 2025-01-21T16:59:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obt-076-oxford-biotherapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-04-23T03:49:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyrotinib-jiangsu-hengrui-medicine-breast-cancer-likelihood-of-approval/ 2025-01-21T16:59:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cedazuridine-decitabine-otsuka-pharmaceutical-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T16:59:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cedazuridine-decitabine-otsuka-pharmaceutical-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T16:59:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vas-01-vasgene-therapeutics-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-21T16:59:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacmilimab-cytomx-therapeutics-metastatic-breast-cancer-likelihood-of-approval/ 2024-04-23T03:47:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabikibart-csl-allergic-asthma-likelihood-of-approval/ 2024-06-19T16:07:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/temtokibart-leo-pharma-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-04-23T03:47:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selinexor-karyopharm-therapeutics-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-21T16:58:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pas-004-pasithea-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T16:58:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-starpharma-ocular-melanoma-likelihood-of-approval/ 2024-07-05T18:27:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-metastatic-uveal-melanoma-likelihood-of-approval/ 2025-01-21T16:58:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-starpharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-23T03:45:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-starpharma-esophageal-cancer-likelihood-of-approval/ 2024-07-05T18:27:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-starpharma-sarcomas-likelihood-of-approval/ 2024-07-05T18:27:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-starpharma-solid-tumor-likelihood-of-approval/ 2024-07-05T18:27:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nadunolimab-cantargia-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-23T03:44:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-starpharma-gastric-cancer-likelihood-of-approval/ 2024-07-05T18:27:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-follicular-lymphoma-likelihood-of-approval/ 2024-04-23T03:44:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/famitinib-jiangsu-hengrui-medicine-cervical-cancer-likelihood-of-approval/ 2024-09-09T05:58:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-pleomorphic-liposarcoma-likelihood-of-approval/ 2025-01-21T16:58:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-ureter-cancer-likelihood-of-approval/ 2025-01-21T16:58:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T16:58:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-dedifferentiated-liposarcoma-likelihood-of-approval/ 2025-01-21T16:58:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T16:58:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T16:58:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-ovarian-cancer-likelihood-of-approval/ 2025-01-21T16:58:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-05-20T05:40:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itezocabtagene-autoleucel-tessa-therapeutics-natural-killer-cell-lymphomas-likelihood-of-approval/ 2024-09-09T05:58:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itezocabtagene-autoleucel-tessa-therapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T05:58:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itezocabtagene-autoleucel-tessa-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T05:57:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itezocabtagene-autoleucel-tessa-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T05:58:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golimumab-johnson-johnson-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-04-23T03:40:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golimumab-johnson-johnson-castration-resistant-prostate-cancer-crpc-likelihood-of-approval/ 2024-04-23T03:40:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelfinavir-mesylate-pfizer-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-04-23T03:39:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-pharmaceuticals-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-09-09T05:57:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-21T16:57:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/filgotinib-maleate-galapagos-giant-lymph-node-hyperplasia-castleman-s-disease-likelihood-of-approval/ 2024-04-23T03:39:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bct-100-bio-cancer-treatment-international-high-grade-glioma-likelihood-of-approval/ 2024-05-20T05:40:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/masitinib-ab-science-asthma-likelihood-of-approval/ 2024-04-23T03:38:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bct-100-bio-cancer-treatment-international-sarcomas-likelihood-of-approval/ 2024-05-20T05:39:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bct-100-bio-cancer-treatment-international-neuroblastoma-likelihood-of-approval/ 2024-05-20T05:39:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afatinib-dimaleate-boehringer-ingelheim-international-refractory-multiple-myeloma-likelihood-of-approval/ 2024-04-23T03:37:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bct-100-bio-cancer-treatment-international-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-05-20T05:39:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensartinib-hydrochloride-betta-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T16:57:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rec-4881-recursion-pharmaceuticals-colorectal-cancer-likelihood-of-approval/ 2024-04-23T03:37:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-incyte-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T16:57:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-188p2045-andarix-pharmaceuticals-squamous-non-small-cell-lung-carcinoma-likelihood-of-approval/ 2025-01-21T16:57:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemafibrate-kowa-primary-biliary-cholangitis-primary-biliary-cirrhosis-likelihood-of-approval/ 2025-01-21T16:57:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saroglitazar-zydus-lifesciences-hypertriglyceridemia-likelihood-of-approval/ 2024-04-23T03:35:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anakinra-swedish-orphan-biovitrum-cytokine-release-syndrome-cytokine-storm-likelihood-of-approval/ 2025-01-21T16:57:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mifepristone-corcept-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-04-23T03:35:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/censavudine-transposon-therapeutics-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2025-01-21T16:56:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/censavudine-transposon-therapeutics-frontotemporal-dementia-ftd-likelihood-of-approval/ 2025-01-21T16:57:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tezepelumab-amgen-churg-strauss-syndrome-likelihood-of-approval/ 2024-04-23T03:34:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tezepelumab-amgen-cat-allergy-likelihood-of-approval/ 2025-01-21T16:56:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enzalutamide-pfizer-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T05:57:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sotagliflozin-lexicon-pharmaceuticals-hypertrophic-cardiomyopathy-likelihood-of-approval/ 2025-01-21T16:56:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-21T16:56:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enzalutamide-pfizer-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T05:57:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-04-23T03:32:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abexinostat-xynomic-pharmaceuticals-mantle-cell-lymphoma-likelihood-of-approval/ 2024-04-23T03:32:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naptumomab-estafenatox-neotx-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-23T03:32:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hyaluronidase-recombinant-human-immune-globulin-human-takeda-pharmaceutical-lymphoma-likelihood-of-approval/ 2024-07-05T18:26:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blinatumomab-amgen-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T16:56:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-04-23T03:31:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-bladder-cancer-likelihood-of-approval/ 2025-01-21T16:56:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neratinib-puma-biotechnology-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T05:57:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-79032421-johnson-johnson-peritoneal-cancer-likelihood-of-approval/ 2024-06-19T16:05:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-79032421-johnson-johnson-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-06-19T16:05:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-79032421-johnson-johnson-malignant-mesothelioma-likelihood-of-approval/ 2024-06-19T16:05:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-79032421-johnson-johnson-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-06-19T16:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-9931-novo-nordisk-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-21T16:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-79032421-johnson-johnson-fallopian-tube-cancer-likelihood-of-approval/ 2024-06-19T16:05:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-931-biomed-industries-obesity-likelihood-of-approval/ 2024-04-23T03:28:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-9931-novo-nordisk-liver-cirrhosis-likelihood-of-approval/ 2024-04-23T03:28:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-604-novartis-solid-tumor-likelihood-of-approval/ 2025-01-21T16:56:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stemvacs-a-therapeutic-solutions-international-solid-tumor-likelihood-of-approval/ 2024-04-23T03:28:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6468-genentech-usa-solid-tumor-likelihood-of-approval/ 2024-04-23T03:27:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046045-pfizer-solid-tumor-likelihood-of-approval/ 2025-01-21T16:55:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6457-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2024-04-23T03:27:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sq-009-seqirus-influenzavirus-a-infections-likelihood-of-approval/ 2024-04-23T03:27:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-112-neogene-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T16:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-112-neogene-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T16:55:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-112-neogene-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T16:55:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-112-neogene-therapeutics-endometrial-cancer-likelihood-of-approval/ 2025-01-21T16:55:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-1664-repare-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-23T03:25:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nt-112-neogene-therapeutics-colorectal-cancer-likelihood-of-approval/ 2025-01-21T16:55:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/platelet-coupled-il-2-cell-injection-zcapsule-pharmaceuticals-shaoxing-solid-tumor-likelihood-of-approval/ 2025-01-21T16:55:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xl-309-exelixis-solid-tumor-likelihood-of-approval/ 2025-01-21T16:55:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/am-003-aummune-therapeutics-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-21T16:55:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/am-003-aummune-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T16:55:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/am-003-aummune-therapeutics-thyroid-cancer-likelihood-of-approval/ 2025-01-21T16:55:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/am-003-aummune-therapeutics-nonmelanomatous-skin-cancer-likelihood-of-approval/ 2025-01-21T16:55:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/am-003-aummune-therapeutics-metastatic-melanoma-likelihood-of-approval/ 2025-01-21T16:54:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/am-003-aummune-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T16:55:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vio-01-valerio-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-04-23T03:22:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/am-003-aummune-therapeutics-head-and-neck-cancer-likelihood-of-approval/ 2025-01-21T16:54:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vio-01-valerio-therapeutics-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-04-23T03:22:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vio-01-valerio-therapeutics-metastatic-prostate-cancer-likelihood-of-approval/ 2024-04-23T03:22:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vio-01-valerio-therapeutics-metastatic-breast-cancer-likelihood-of-approval/ 2024-04-23T03:21:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vio-01-valerio-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-23T03:21:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-0525-ctx-operations-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-04-23T03:21:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-0525-ctx-operations-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-04-23T03:21:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/npx-887-nextpoint-therapeutics-non-small-cell-lung-carcinoma-likelihood-of-approval/ 2024-04-23T03:20:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-0525-ctx-operations-solid-tumor-likelihood-of-approval/ 2024-04-23T03:20:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/npx-887-nextpoint-therapeutics-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-04-23T03:20:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/npx-887-nextpoint-therapeutics-lung-adenocarcinoma-likelihood-of-approval/ 2024-04-23T03:20:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/npx-887-nextpoint-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-23T03:19:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/npx-887-nextpoint-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-04-23T03:19:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3841136-eli-lilly-and-co-obesity-likelihood-of-approval/ 2024-04-23T03:19:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/npx-887-nextpoint-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-23T03:19:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-04-23T03:18:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-133-innovent-biologics-solid-tumor-likelihood-of-approval/ 2025-01-21T16:54:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afnt-211-affini-t-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T05:56:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afnt-211-affini-t-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-09-09T05:56:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afnt-211-affini-t-therapeutics-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:56:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afnt-211-affini-t-therapeutics-solid-tumor-likelihood-of-approval/ 2024-09-09T05:56:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-7122-ono-pharmaceutical-solid-tumor-likelihood-of-approval/ 2024-06-19T16:04:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-6212-gilead-sciences-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-04-23T03:16:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-rectal-cancer-likelihood-of-approval/ 2024-07-05T18:23:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-esophageal-cancer-likelihood-of-approval/ 2024-07-05T18:23:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-renal-cell-carcinoma-likelihood-of-approval/ 2024-07-05T18:23:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:23:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-07-05T18:23:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-glioma-likelihood-of-approval/ 2024-07-05T18:23:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-gastric-cancer-likelihood-of-approval/ 2024-07-05T18:23:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-hepatocellular-carcinoma-likelihood-of-approval/ 2024-07-05T18:23:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-colon-cancer-likelihood-of-approval/ 2024-07-05T18:23:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2024-07-05T18:23:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-breast-cancer-likelihood-of-approval/ 2024-07-05T18:23:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ast-001-ascentawits-pharmaceuticals-prostate-cancer-likelihood-of-approval/ 2024-07-05T18:23:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imp-17-eikon-therapeutics-peritoneal-cancer-likelihood-of-approval/ 2024-04-23T03:13:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imp-17-eikon-therapeutics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-04-23T03:13:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imp-17-eikon-therapeutics-metastatic-breast-cancer-likelihood-of-approval/ 2024-04-23T03:12:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imp-17-eikon-therapeutics-fallopian-tube-cancer-likelihood-of-approval/ 2024-04-23T03:12:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-modified-cell-therapy-to-target-cd7-for-oncology-suzhou-fundamenta-therapeutics-t-cell-acute-lymphocytic-leukemia-t-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-04-23T03:11:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imp-17-eikon-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-04-23T03:11:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cusp-06-oncusp-therapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-21T16:54:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cusp-06-oncusp-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T16:54:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qtx-3034-quanta-therapeutics-solid-tumor-likelihood-of-approval/ 2024-09-09T05:56:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qtx-3034-quanta-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-09-09T05:56:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qtx-3034-quanta-therapeutics-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:56:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qtx-3034-quanta-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T05:56:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xbh-25-gv20-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-06-19T16:04:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qtx-3034-quanta-therapeutics-lung-cancer-likelihood-of-approval/ 2024-04-23T03:09:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xbh-25-gv20-therapeutics-adenocarcinoma-likelihood-of-approval/ 2024-06-19T16:04:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xbh-25-gv20-therapeutics-bladder-carcinoma-likelihood-of-approval/ 2024-06-19T16:04:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xbh-25-gv20-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-06-19T16:04:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xbh-25-gv20-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T16:04:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-01488-transthera-sciences-nanjing-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T16:04:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xbh-25-gv20-therapeutics-melanoma-likelihood-of-approval/ 2024-06-19T16:04:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-01488-transthera-sciences-nanjing-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T16:04:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-01488-transthera-sciences-nanjing-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-06-19T16:04:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-400-abbvie-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T05:56:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-01488-transthera-sciences-nanjing-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-06-19T16:04:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-400-abbvie-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-09-09T05:56:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-400-abbvie-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-05T18:23:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-400-abbvie-solid-tumor-likelihood-of-approval/ 2024-09-09T05:56:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-400-abbvie-renal-cell-carcinoma-likelihood-of-approval/ 2024-09-09T05:56:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-400-abbvie-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:55:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-400-abbvie-gastric-cancer-likelihood-of-approval/ 2024-09-09T05:55:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fmc-376-frontier-medicines-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-23T03:04:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fmc-376-frontier-medicines-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-04-23T03:04:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fmc-376-frontier-medicines-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-04-23T03:04:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fmc-376-frontier-medicines-solid-tumor-likelihood-of-approval/ 2024-04-23T03:04:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olx-75016-olix-pharmaceuticals-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-07-05T18:22:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olx-75016-olix-pharmaceuticals-metabolic-dysfunction-associated-steatotic-liver-disease-masld-likelihood-of-approval/ 2024-07-05T18:22:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olomorasib-eli-lilly-and-co-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T16:03:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olx-75016-olix-pharmaceuticals-liver-cirrhosis-likelihood-of-approval/ 2024-07-05T18:22:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olomorasib-eli-lilly-and-co-solid-tumor-likelihood-of-approval/ 2024-06-19T16:03:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olomorasib-eli-lilly-and-co-endometrial-cancer-likelihood-of-approval/ 2024-06-19T16:03:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olomorasib-eli-lilly-and-co-colorectal-cancer-likelihood-of-approval/ 2024-06-19T16:02:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olomorasib-eli-lilly-and-co-pancreatic-cancer-likelihood-of-approval/ 2024-06-19T16:03:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cpi-300-coordination-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-04-23T03:01:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olomorasib-eli-lilly-and-co-ovarian-cancer-likelihood-of-approval/ 2024-06-19T16:02:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-04-23T03:01:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-04-23T03:01:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-peritoneal-cancer-likelihood-of-approval/ 2024-04-23T13:27:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-04-23T03:00:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-04-23T02:59:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-ureter-cancer-likelihood-of-approval/ 2024-04-23T03:00:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/spurred-by-rise-in-deals-experts-say-adc-innovation-is-set-to-advance/ 2024-04-22T17:25:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hyundai-to-advance-cancer-study-plans-for-niclosamide-based-drug/ 2024-04-22T16:12:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/tymlos-outperforms-teriparatide-real-world-fracture-analysis/ 2024-04-22T14:39:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chiesi-champions-new-inhaler-propellant-to-reduce-carbon-footprint/ 2024-04-22T17:15:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/silence-therapeutics-gets-grant-for-compound-for-rna-interference-therapy-in-liver-disease/ 2024-04-22T12:28:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syros-pharmaceuticals-gets-grant-for-cdk7-inhibitors-for-treating-cancer-and-other-diseases/ 2024-04-22T12:27:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biomarin-pharmaceutical-gets-grant-for-treatment-of-adolescent-pku-patients-using-avpal-variant/ 2024-04-22T12:27:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ultragenyx-pharmaceutical-gets-grant-for-method-of-developing-stable-cell-line-for-producing-raav/ 2024-04-22T12:27:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/united-laboratories-international-gets-grant-for-jak-inhibitor-compound-for-treating-jak1-tyk2-related-diseases/ 2024-04-22T12:27:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eurofins-scientific-gets-grant-for-method-to-detect-cancer-in-human-individual-using-cell-free-dna/ 2024-04-22T12:26:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arvinas-gets-grant-for-bifunctional-compounds-for-modulating-tau-protein/ 2024-04-22T12:26:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teladoc-health-gets-grant-for-contextual-video-searching-method-for-telepresence-devices/ 2024-04-22T12:26:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/purdue-pharma-gets-grant-for-treatment-of-t-cell-prolymphocytic-leukemia-using-tinostamustine/ 2024-04-22T12:26:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/genexine-gets-grant-for-treatment-of-hpv-induced-cancer-using-combination-of-hpv-vaccine-and-checkpoint-inhibitor/ 2024-04-22T12:25:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esperion-therapeutics-gets-grant-for-preserving-and-administering-pre-beta-high-density-lipoprotein-plasma/ 2024-04-22T12:25:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allakos-gets-grant-for-anti-siglec-7-antibody-with-reduced-effector-function-for-cancer-treatment/ 2024-04-22T12:25:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/csl-gets-grant-for-adjuvanted-influenza-vaccine-for-reducing-elderly-hospitalization-for-respiratory-illness/ 2024-04-22T12:25:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chong-kun-dang-pharmaceutical-gets-grant-for-pharmaceutical-composition-for-gastritis-peptic-ulcer-treatment-using-cinnamomum-cassia-extract/ 2024-04-22T12:24:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/angelini-gets-grant-for-parcel-handling-and-tracking-system-with-light-permeable-scanning-window/ 2024-04-22T12:24:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zealand-pharma-gets-grant-for-novel-acylated-glucagon-analogue-peptides-for-treating-metabolic-disorders-2/ 2024-04-22T12:24:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sun-pharmaceutical-industries-gets-grant-for-hair-loss-treatment-using-jak1-jak2-inhibitor-compound/ 2024-04-22T12:24:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ptc-therapeutics-gets-grant-for-treatment-of-huntington-s-disease-using-compound-of-formula-ibbl-2/ 2024-04-22T12:23:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senju-pharmaceutical-gets-grant-for-treatment-of-retinal-and-nerve-diseases-with-laminin-and-cells/ 2024-04-22T12:23:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-inhibiting-coronavirus-replication-with-compound-of-formula-i-2/ 2024-04-22T12:23:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/indivior-gets-grant-for-medication-mixing-system-with-female-and-male-syringes/ 2024-04-22T12:23:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arbutus-biopharma-gets-grant-for-method-of-treating-infusion-reaction-with-lipid-formulated-therapeutic-agent/ 2024-04-22T12:22:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orexo-gets-grant-for-patent-granted-for-nasal-delivery-of-opioid-antagonist/ 2024-04-22T12:22:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sorrento-therapeutics-gets-grant-for-implantable-device-for-delivering-bioactive-agents-without-immune-response/ 2024-04-22T12:22:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zhejiang-huahai-pharmaceutical-gets-grant-for-method-for-preparing-pregabalin-using-biological-enzymes/ 2024-04-22T12:22:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ardelyx-gets-grant-for-compound-inhibiting-enzyme-11-hsd2-for-treating-hyperkalemia/ 2024-04-22T12:21:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biogaia-gets-grant-for-lactic-acid-bacterial-strains-producing-melatonin-for-therapeutic-uses/ 2024-04-22T12:21:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/protagonist-therapeutics-gets-grant-for-peptide-inhibitors-for-treating-inflammatory-bowel-disease-2/ 2024-04-22T12:21:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shilpa-medicare-gets-grant-for-pharmaceutical-liposomal-composition-with-docetaxel-for-cancer-treatment-2/ 2024-04-22T12:21:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immunogen-gets-grant-for-immunoconjugates-binding-to-cd123-antigen-for-treating-diseases/ 2024-04-22T12:20:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eli-lilly-and-co-gets-grant-for-patent-granted-for-mapt-rnai-agent-for-tauopathy-treatment/ 2024-04-22T12:20:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iovance-biotherapeutics-gets-grant-for-gene-edited-til-composition-with-enhanced-ifn-secretion/ 2024-04-22T12:20:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iveric-bio-gets-grant-for-nucleic-acid-therapeutic-for-complement-related-disorders/ 2024-04-22T12:19:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radius-health-gets-grant-for-patent-granted-for-treating-prader-willi-syndrome-with-cannabidiol-formulation/ 2024-04-22T12:19:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teva-pharmaceutical-industries-gets-grant-for-inhaler-with-lock-system-for-inhalable-substances/ 2024-04-22T12:19:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/voyager-therapeutics-gets-grant-for-enhanced-aav-capsid-for-brain-cell-targeting-2/ 2024-04-22T12:19:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elanco-animal-health-gets-grant-for-eye-drop-composition-for-herpetic-eye-infections-in-animals/ 2024-04-22T12:18:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-gets-grant-for-treatment-of-lung-cancer-with-tim-3-binding-agents/ 2024-04-22T12:18:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aldeyra-therapeutics-gets-grant-for-treatment-of-retinitis-pigmentosa-with-methotrexate-eye-injections/ 2024-04-22T12:18:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pmv-pharmaceuticals-gets-grant-for-compounds-restoring-dna-binding-affinity-of-p53-mutants/ 2024-04-22T12:18:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avidity-biosciences-gets-grant-for-polynucleic-acid-conjugate-for-treating-fshd-through-rna-interference/ 2024-04-22T12:17:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/synlogic-gets-grant-for-genetically-engineered-bacteria-for-attenuating-metabolic-diseases/ 2024-04-22T12:17:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wave-life-sciences-gets-grant-for-improved-method-for-synthesizing-phosphoramidites-with-higher-yields-and-purities-2/ 2024-04-22T12:17:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ose-immunotherapeutics-gets-grant-for-humanized-monoclonal-antibodies-targeting-cd127-for-therapeutic-and-diagnostic-use/ 2024-04-22T12:17:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ovid-therapeutics-gets-grant-for-treatment-of-status-epilepticus-with-ganaxolone-continuous-intravenous-infusion/ 2024-04-22T12:16:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spruce-biosciences-gets-grant-for-treatment-of-polycystic-ovary-syndrome-with-adrenal-hyperandrogenism-2/ 2024-04-22T12:16:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/recursion-pharmaceuticals-gets-grant-for-pharmaceutical-compounds-for-treating-diseases/ 2024-04-22T12:16:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abcellera-biologics-gets-grant-for-enhanced-production-of-diverse-antibodies-using-genetically-modified-mice/ 2024-04-22T12:16:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pieris-pharmaceuticals-gets-grant-for-fusion-polypeptide-binding-cd137-and-gpc3-for-cancer-treatment/ 2024-04-22T12:15:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-astellas-smbc-jv/ 2024-04-22T10:43:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/health-canada-nora-niopeg/ 2024-04-22T10:46:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bioarctic-eisai-alzheimers-treatment/ 2024-04-22T08:54:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/health-canada-merck-keytruda-cancer/ 2024-04-22T08:44:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2024-04-20T05:01:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-fallopian-tube-cancer-likelihood-of-approval/ 2024-04-20T05:01:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-20T05:01:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-endometrial-cancer-likelihood-of-approval/ 2024-04-20T05:00:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-solid-tumor-likelihood-of-approval/ 2024-04-20T05:00:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-bladder-cancer-likelihood-of-approval/ 2024-04-20T05:00:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1107-profoundbio-suzhou-gastric-cancer-likelihood-of-approval/ 2024-04-20T05:00:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-4101-abbvie-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-04-20T04:59:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-4101-abbvie-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-20T04:59:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-4101-abbvie-renal-cell-carcinoma-likelihood-of-approval/ 2024-04-20T04:59:09+00:00 daily 0.2